Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib and Endocrine Therapy for Locoregional Recurrent HR+/HER2- Breast Cancer
NCT05467891Phase 2Recruiting
- Sponsor
- Oana Danciu
- Start
- Sep 2022
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Oana Danciu. Primary endpoint: Recurrence Free Survival at 3 years. Started Sep 2022; status: recruiting.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05467891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05467891.